Increased incidence of systemic serious viral infections in patients with inflammatory bowel disease associates with active disease and use of thiopurines
Open Access
- 14 November 2019
- journal article
- research article
- Published by Wiley in United European Gastroenterology Journal
- Vol. 8 (3), 303-313
- https://doi.org/10.1177/2050640619889763
Abstract
The magnitude and drivers of the risk of serious viral infections in Inflammatory Bowel diseases (IBD) are unclear. The objective of this study was to assess the incidence and risk factors for systemic serious viral infections in IBD patients. Using MICISTA, a database detailing prospective characteristics and complications of IBD, we identified patients that were followed for IBD in 2005–2014 outside the context of organ transplantation, HIV infection or chronic viral hepatitis. We estimated incidences of systemic serious viral infections, defined by the need for hospitalization or permanent organ damage. Standardized incidence ratios (SIRs) were calculated using the French hospital database. We performed a case-control study nested in MICISTA for assessing the role of exposure to IBD drugs and IBD clinical activity in the risk of developing infection. We identified 31 patients with serious viral infections among 2645 patients followed for 15,383 person-years. We observed 13 cases of cytomegalovirus, 10 Epstein–Barr virus, 5 varicella zoster virus and 3 herpes simplex virus infections. No deaths occurred. The incidence rate of infections in patients with IBD was 2.02/1000 person-years, and the SIR was 3.09 (95% confidence interval (CI), 1.98–4.20; p = 0.0002) in the study population. By multivariate analysis, increased risk of infection was associated with exposure to thiopurines (odds ratio (OR), 3.48; 95% CI, 1.36–8.90; p = 0.009), and clinically active IBD at onset of infection (OR, 3.35; 95% CI, 1.23–9.23; p = 0.02). The incidence of systemic serious viral infections in patients with IBD is tripled compared to general population. Clinically active IBD and exposure to thiopurines are the main drivers of the risk.Keywords
This publication has 34 references indexed in Scilit:
- Increased risk of herpes zoster among 108 604 patients with inflammatory bowel diseaseAlimentary Pharmacology & Therapeutics, 2012
- Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ RegistryThe American Journal of Gastroenterology, 2012
- Association of Crohn’s Disease, Thiopurines, and Primary Epstein-Barr Virus Infection with Hemophagocytic LymphohistiocytosisThe Journal of Pediatrics, 2011
- Advanced Age Is an Independent Risk Factor for Severe Infections and Mortality in Patients Given Anti–Tumor Necrosis Factor Therapy for Inflammatory Bowel DiseaseClinical Gastroenterology and Hepatology, 2011
- Fatal varicella in an immunocompromised adult associated with a European genotype E2 variant of varicella zoster virusJournal of Clinical Virology, 2009
- Cytomegalovirus infection in inflammatory bowel disease patients undergoing anti-TNFα therapyJournal of Clinical Virology, 2008
- Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort studyGut, 2008
- Risk Factors for Opportunistic Infections in Patients With Inflammatory Bowel DiseaseGastroenterology, 2008
- Incidence and Risk Factors for Herpes Zoster Among Patients With Inflammatory Bowel DiseaseClinical Gastroenterology and Hepatology, 2006
- HLH‐2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosisPediatric Blood & Cancer, 2006